Nanobiotix logo

Nanobiotix(NASDAQ) NBTX

Market Cap$1.19BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)+38%
5 Year+91%
1 Year-1%
1 Month-37%
Premium Feature
Moneyball Superscore
60/100
$21.66
-7.46%
-1.74Today
After hours$21.54-$0.11 (-0.53%)
Nanobiotix last closing stock price
MetricPriceDate
Last closeUSD 23.402026-10-12
Nanobiotix stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-6.77%USD 25.102026-10-05
1 month-36.77%USD 37.012026-09-11
3 month-43.8%USD 41.642026-07-14
Year to date+1.21%USD 23.122025-12-31
1 year-0.85%USD 23.602025-10-10
3 year+249.25%USD 6.702023-10-13
5 year+90.55%USD 12.282021-10-13
Since inception+37.81%USD 16.982020-12-11

Nanobiotix Financials at a Glance

Market Cap

$1.19BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€18.72M

Net Income (TTM)

-€104.97M

EPS (TTM)

-$1.27

P/E Ratio

-18.48

Dividend

$0.00

Beta (Volatility)

0.87 (Low)

Price

$21.66

Volume

231,305.371

Open

$23.11

Previous Close

$21.49

Daily Range

$21.22 - $23.11

52-Week Range

$14.78 - $57.14

Estimated Earnings Date

Apr 27, 2027

NBTX News

Getty - happy foursome celebrating victory

Biotech Stock Nanobiotix (NBTX) Is Up 660% This Year -- Here's Why the Rally Could Continue

Selena MaranjianNov 24, 2025

NBTX: Motley Fool Moneyball Superscore

60

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Nanobiotix

Nanobiotix S.A. is a clinical-stage biotechnology firm dedicated to developing innovative therapeutic solutions for cancer. The company's flagship experimental drug, NBTXR3, utilizes crystalline hafnium oxide nanoparticles and is being tested for various cancer types.

Products and Services
  • NBTXR3, an innovative treatment for multiple cancer types
  • Strategic collaboration with LianBio for Asian market expansion
  • Focus on research and development in oncology
Growth Outlook
  • Recent quarterly revenue reached €3,005,000, showing potential for growth
  • Strategic partnerships may enhance market penetration in Asia
  • Ongoing clinical trials could lead to significant product advancements
Financial Highlights
  • Trailing twelve months (TTM) revenue of €26,638,000 indicates strong market interest
  • Cash and cash equivalents stood at €52,750,000 as of Q4 2025
  • Operating expenses totaled €14,631,000 in the latest quarter, reflecting ongoing investment in R&D
Nanobiotix S.A. operates in the dynamic biotechnology sector, focusing on innovative cancer therapies. The company’s lead product, NBTXR3, is currently in clinical trials for various cancers, which positions it well for future growth. The strategic collaboration with LianBio aims to expand its reach into key Asian markets, potentially increasing revenue streams. Recent financial data shows a revenue of €3,005,000 for the latest quarter, with a TTM revenue of €26,638,000, indicating a solid foundation for future growth. The company maintains a healthy cash position, with €52,750,000 in cash and cash equivalents, allowing for continued investment in research and development. Operating expenses reflect a commitment to advancing its product pipeline, which may lead to significant breakthroughs in cancer treatment.
AI Generated • Sep 22, 2026

Industry

Biotechnology

Sector

Health Care

Employees

97

CEO

Laurent Lévy, PhD

Website

www.nanobiotix.com

Headquarters

Paris, IF 75012, FR

NBTX Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-367.66%

Net Income Margin

-617.88%

Return on Equity

89.71%

Return on Capital

-99.83%

Return on Assets

-41.20%

Earnings Yield

-5.41%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.19BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

50.80M

Volume

231.31K

Avg. Volume

150.16K

Financials (TTM)

Gross Profit

€18.72M

Operating Income

-€73.48M

EBITDA

-€75.15M

Operating Cash Flow

-€69.46M

Capital Expenditure

-€1.54M

Free Cash Flow

-€71.00M

Cash & ST Invst.

€110.85M

Total Debt

€106.57M

Nanobiotix Performance Analysis

Nanobiotix annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 0N/A
20232023-12-31EUR 32,496,173N/A
20242024-12-31EUR -12,557,348N/A
20252025-12-31EUR 33,454,436N/A
Nanobiotix sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-277.4%
Q22025-06-30261.6%
Q42025-12-31-88.7%
Q22026-06-3084.7%
Nanobiotix annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR -1.727.5%
20232023-12-31EUR -1.16-32.4%
20242024-12-31EUR -1.5634.1%
20252025-12-31EUR -0.57-63.7%
Nanobiotix sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-113.0%
Q22025-06-3088.8%
Q42025-12-31-254.5%
Q22026-06-30-82.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€5.55M

-40.2%

Gross Profit

€5.55M

-40.2%

Gross Margin

100.00%

N/A

Market Cap

$1.19BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$12.26M

N/A

Employees

97

N/A

Net Income

-€34.75M

-58.9%

EBITDA

-€19.30M

+15.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€110.85M

+67.1%

Total Debt

€106.57M

+116.7%

Accounts Receivable

€9.37M

+200.1%

Inventory

€0.00

N/A

Long Term Debt

€74.52M

+68.7%

Short Term Debt

€32.05M

+541.0%

Return on Assets

-41.20%

N/A

Return on Invested Capital

-74.19%

N/A

Free Cash Flow

-€22.96M

-263.0%

Operating Cash Flow

-€22.33M

-282.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SNDXSyndax Pharmaceuticals, Inc.
$13.95-15.71%
TYRATyra Biosciences, Inc.
$18.56-5.31%
KURAKura Oncology, Inc.
$9.83-5.44%
AVBPArriVent BioPharma, Inc.
$16.09-2.25%

Trending Stocks

Symbol / CompanyPricePrice Chg
CIFRCipher Digital
$11.34-12.77%
BMBLBumble
$5.95+56.58%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$37.42+0.62%
INTCIntel
$102.81+1.44%

Questions About NBTX

What is the current price of Nanobiotix?

Nanobiotix is trading at $21.49 per share.

What is the 52-week range for Nanobiotix?

Over the past 52 weeks, Nanobiotix has traded between $14.78 and $57.14.

How much debt does Nanobiotix have?

As of the most recent reporting period, Nanobiotix reported total debt of €111.95M.

How much cash does Nanobiotix have on hand?

Nanobiotix reported €61.95M in cash and cash equivalents in its most recent financial results.

What is Nanobiotix’s dividend yield?

Nanobiotix does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services